Specific patterns of gyrA mutations determine the resistance difference to ciprofloxacin and levofloxacin in Klebsiella pneumoniae and Escherichia coli

BMC Infectious Diseases

Fengmin Zhang³  Xiaobei Chen³  Hui Xu⁴  Ying Zhang⁴  Fanfei Meng⁴  Yang Chen⁴  Song Zhao¹  Hong Wang²  Wenli Zhang⁴  Yingmei Fu⁴ 

[1] Department of General Surgery, Minimally Invasive Surgery, First Affiliated Hospital, Harbin Medical University, Harbin, 150010, China;Current address: The First Hospital of Qiqihaer City, 30 Gongyuan Road, Qiqihaer, 161005, China;Bio-pharmaceutical Key Laboratory of Ministry of Education, Harbin Medical University, Harbin, China;Department of Microbiology, Heilongjiang Province Key Laboratory for Immunity and infection, Pathogenic biology, Bio-pharmaceutical Key Laboratory of Ministry of Education, Harbin Medical University, 157 Baojian Road, Harbin, 150086, China

关键词: GyrA;    Fluoroquinolone resistance;    Enterobacteriaceae;   

Others  :  1158611
DOI  :  10.1186/1471-2334-13-8

 received in 2012-07-24, accepted in 2013-01-02,  发布年份 2013

【 摘 要 】

Background

Wide use of ciprofloxacin and levofloxacin has often led to increased resistance. The resistance rate to these two agents varies in different clinical isolates of Enterobacteriaceae. Mutations of GyrA within the quinolone resistance-determining regions have been found to be the main mechanism for quinolone resistance in Enterobacteriaceae. It has been shown that only some of the mutations in the gyrA gene identified from clinical sources were involved in fluoroquinolone resistance. Whether different patterns of gyrA mutation are related to antimicrobial resistance against ciprofloxacin and levofloxacin is unclear.

Methods

The minimum inhibitory concentration (MIC) of ciprofloxacin and levofloxacin were determined by the agar dilution method followed by PCR amplification and sequencing of the quinolone resistance determining region of gyrA to identify all the mutation types. The correlation between fluoroquinolone resistance and the individual mutation type was analyzed.

Results

Resistance differences between ciprofloxacin and levofloxacin were found in 327 isolates of K. pneumoniae and E. coli in Harbin, China and in the isolates reported in PubMed publications. GyrA mutations were found in both susceptible and resistant isolates. For the isolates with QRDR mutations, the resistance rates to ciprofloxacin and levofloxacin were also statistically different. Among the 14 patterns of alterations, two single mutations (Ser83Tyr and Ser83Ile), and three double mutations (Ser83Leu+Asp87Asn, Ser83Leu+Asp87Tyr and Ser83Phe+Asp87Asn) were associated with both ciprofloxacin and levofloxacin resistance. Two single mutations (Ser83Phe and Ser83Leu) were related with ciprofloxacin resistance but not to levofloxacin. Resistance difference between ciprofloxacin and levofloxacin in isolates harboring mutation Ser83Leu+Asp87Asn were of statistical significance among all Enterobacteriaceae (P<0.001).

Conclusions

Resistance rate to ciprofloxacin and levofloxacin were statistically different among clinical isolates of Enterobacteriaceae harboring GyrA mutations. Ser83Leu+Asp87Asn may account for the antimicrobial resistance difference between ciprofloxacin and levofloxacin.

【 授权许可】

   
2013 Fu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Becnel Boyd L, Maynard MJ, Morgan-Linnell SK, Horton LB, Sucgang R, Hamill RJ, Jimenez JR, Versalovic J, Steffen D, Zechiedrich L: Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates. Antimicrob Agents Chemother 2009, 53(1):229-234.
• [2]Malik M, Marks KR, Schwanz HA, German N, Drlica K, Kerns RJ: Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality. Antimicrob Agents Chemother 2010, 54:5214-5221.
• [3]Lu T, Zhao X, Li X, Drlica-Wagner A, Wang JY, Domagala J, Drlica K: Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of staphylococcus aureus. Antimicrob Agents Chemother 2001, 45:2703-2709.
• [4]Dalhoff A: Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118. Clin Infect Dis 2001, 32:S16-S22.
• [5]Kitamura A, Hoshino K, Kimura Y, Hayakawa I, Sato K: Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of pseudomonas aeruginosa. Antimicrob Agents Chemother 1995, 39:1467-1471.
• [6]Brink AJ, Botha RF, Poswa X, Senekal M, Badal RE, Grolman DC, Richards GA, Feldman C, Boffard KD, Veller M, Joubert I, Pretorius J: Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in south African hospitals (SMART study 2004–2009): impact of the new carbapenem breakpoints. Surg Infect (Larchmt) 2012, 13:43-49.
• [7]Brisse S, Milatovic D, Fluit AC, Verhoef J, Martin N, Scheuring S, Köhrer K, Schmitz FJ: Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins. Antimicrob Agents Chemother 1999, 43:2051-2055.
• [8]Chen WY, Jang TN, Huang CH, Hsueh PR: In vitro susceptibilities of aerobic and facultative anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections at a medical center in Taiwan: results of the study for monitoring antimicrobial resistance trends (SMART) 2002–2006. J Microbiol Immunol Infect 2009, 42:317-323.
• [9]Hoban DJ, Nicolle LE, Hawser S, Bouchillon S, Badal R: Antimicrobial susceptibility of global inpatient urinary tract isolates ofEscherichia coli: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009–2010. Diagn Microbiol Infect Dis 2011, 70:507-511.
• [10]Lee SJ, Lee DS, Choe HS, Shim BS, Kim CS, Kim ME, Cho YH: Antimicrobial resistance in community-acquired urinary tract infections: results from the Korean antimicrobial resistance monitoring system. J Infect Chemother 2011, 17:440-446.
• [11]Rhomberg PR, Jones RN: Summary trends for the meropenem yearly susceptibility test information collection program: a 10-year experience in the united states (1999–2008). Diagn Microbiol Infect Dis 2009, 65:414-426.
• [12]Fu Y, Guo L, Xu Y, Zhang W, Gu J, Xu J, Chen X, Zhao Y, Ma J, Liu X, Zhang F: Alteration of GyrA amino acid required for ciprofloxacin resistance in Klebsiella pneumoniae isolates in china. Antimicrob Agents Chemother 2008, 52(8):2980-2983.
• [13]Drago L, Nicola L, Mattina R, De Vecchi E: In vitro selection of resistance in Escherichia coli and Klebsiella spp. At in vivo fluoroquinolone concentrations. BMC Microbiol 2010, 10:119. BioMed Central Full Text
• [14]Clinical and Laboratory Standards Institute: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-eighth edition (M07-A8). PA, USA, CLSI: Wayne; 2009.
• [15]Chen JY, Siu LK, Chen YH, Lu PL, Ho M, Peng CF: Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center. Microb Drug Resist 2001, 7:47-53.
• [16]Lawrence LE, Wu P, Fan L, Gouveia KE, Card A, Casperson M, Denbleyker K, Barrett JF: The inhibition and selectivity of bacterial topoisomerases by BMS-284756 and its analogues. J Antimicrob Chemother 2001, 48:195-201.
• [17]Morgan-Linnell SK, Becnel Boyd L, Steffen D, Zechiedrich L: Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob Agents Chemother 2009, 53:235-241.
• [18]Uchida Y, Mochimaru T, Morokuma Y, Kiyosuke M, Fujise M, Eto F, Harada Y, Kadowaki M, Shimono N, Kang D: Geographic distribution of fluoroquinolone-resistant Escherichia coli strains in Asia. Int J Antimicrob Agents 2010, 35:387-391.
• [19]Weigel LM, Steward CD, Tenover FC: GyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob Agents Chemother 1998, 42:2661-2667.
• [20]Yoshida H, Bogaki M, Nakamura M, Nakamura S: Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother 1990, 34:1271-1272.
• [21]Morgan-Linnell SK, Zechiedrich L: Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 2007, 51:4205-4208.
• [22]Lu T, Zhao X, Drlica K: Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. Antimicrob Agents Chemother 1999, 43:2969-2974.
• [23]Karczmarczyk M, Martins M, Quinn T, Leonard N, Fanning S: Mechanisms of fluoroquinolone resistance in Escherichia coli isolates from food-producing animals. Appl Environ Microbiol 2011, 77:7113-7120.